Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea (HMP Korea)

28 juli 2026 bijgewerkt door: Seul Ki Choi

Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea

This study tests a mobile application (app) designed to support sexual health and prevent human immunodeficiency virus (HIV) among young men in South Korea. Researchers are interested to learn if the app is acceptable, easy to use, and helpful for young men who have sex with men (MSM).

Participants will complete a 15-minute online survey at the start of the study and another 15-minute survey 3 months later. Participants will be randomly assigned to 1 of 2 study groups for 3 months:

  1. Intervention Group: Participants receive access to the full mobile app, called Bandi. The app includes health articles, quizzes, community discussion forums, a personal sexual health log, and a clinic finder.
  2. Control Group: Participants receive access to a basic version of the app that includes informational articles and the clinic finder only.

Researchers will compare both groups over 3 months to see if using the full app leads to higher rates of HIV testing and lower sexual risk behaviors.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

This pilot study evaluates Bandi, a culturally adapted digital HIV prevention intervention for young Korean men who have sex with men (MSM). Bandi is adapted from HealthMpowerment (HMP 2.0), an evidence-informed, status-neutral digital health platform designated by the U.S. Centers for Disease Control and Prevention (CDC) for HIV risk reduction. Guided by Barrera and Castro's heuristic model for cultural adaptation, the trial represents Phase 3 (preliminary adaptation testing) following preliminary information gathering and beta testing (N=10).

Participants randomized to the full intervention arm receive 3-month access to the complete Bandi platform, consisting of five core integrated components:

  1. Resource Center (Activities & Articles): Culturally tailored educational materials, pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) adherence strategies, interactive quizzes, and skill-building activities.
  2. Forums: Moderated online discussion forums and structured polls facilitating peer-to-peer support on topics including relationships, stigma, and sexual health.
  3. Love Log: An interactive self-monitoring tool allowing users to log past sexual encounters, plan future encounters, track behavioral patterns, and evaluate risk.
  4. Care Locator: A map database identifying local, culturally sensitive HIV and STI testing facilities.
  5. Gamification: Engagement features including customizable avatars and accomplishment badges.

The control arm receives access restricted to static health articles and the Care Locator component.

The study is conducted remotely in South Korea through a partnership between the University of Pennsylvania and Ewha Womans University. Local recruitment and participant communication are managed by trained staff at Ewha Womans University in collaboration with community stakeholder collectives.

In addition to self-reported web-based survey data (Qualtrics) collected at baseline and 3 months, application engagement will be continuously monitored via passively recorded paradata (e.g., module usage, login frequency, feature interactions). Statistical analyses will follow an intent-to-treat (ITT) approach. Chi-square/Fisher's Exact tests and Wilcoxon Two-Sample tests will evaluate preliminary differences between study arms regarding primary outcomes (routine HIV testing rates, reduction in condomless anal intercourse) and secondary outcomes (PrEP awareness/uptake, everyday discrimination, social support, depression, anxiety, and resilience).

Studietype

Ingrijpend

Inschrijving (Geschat)

50

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

  • Zuid -Korea
      • Seoul, Zuid -Korea
        • Ewha Womans University
        • Contact:
        • Hoofdonderzoeker:
          • Sook Jung Kang, PhD, FNP-C

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • Male sex assigned at birth and current male gender identity
  • Aged 18 to 35 years
  • Current residence in the Seoul Metropolitan area
  • Korean nationality
  • Self-identify as a sexual minority (e.g., gay, bisexual, queer, or other non-heterosexual identity)
  • HIV-negative or HIV-unaware serostatus
  • Report at least 1 episode of condomless anal intercourse with a male partner in the prior 6 months

Exclusion Criteria:

  • Assigned female at birth or do not currently identify as male
  • Younger than 18 or older than 35 years of age
  • Non-residence in the Seoul Metropolitan area
  • Do not hold Korean nationality
  • Do not identify as a sexual minority
  • Known HIV-positive status
  • No reported episodes of condomless anal intercourse with a male partner in the prior 6 months

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Bandi App (Full Access)
Participants in this arm receive full 3-month access to the complete Bandi mobile application. Key features include interactive health articles and quizzes, moderated peer community forums and polls, the Love Log (a sexual health self-monitoring tool), a HIV/STI care locator, and gamification elements (custom avatars and accomplishment badges).
Gedragsmatig: Bandi Mobile Application (Full Access)
A culturally adapted digital HIV prevention mobile application designed for young men who have sex with men (MSM) in South Korea. Participants receive 3-month access to five core integrated features: interactive health articles and quizzes (covering PrEP, adherence, and sexual health); moderated peer community discussion forums and polls; Love Log (a sexual health tracking and planning tool); Care Locator (a directory of local HIV/STI testing centers); and gamification elements (customizable avatars and badges).
Actieve vergelijker: Information-Only App (Limited Access)
Participants in this arm receive 3-month access to a limited version of the mobile application. Features are restricted to static educational articles and a care locator.
Gedragsmatig: Information-Only Mobile Application (Limited Access)
A limited version of the mobile application provided to the control group over a 3-month period. Access is restricted to static online educational articles/resources and the Care Locator feature for finding local HIV/STI testing centers.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of Participants Who Reported Receiving an HIV Test
Tijdsspanne: 3 months post-randomization
Self-reported status of receiving an HIV test (Yes/No) as assessed via a web-based survey.
3 months post-randomization
Change in Frequency of Condomless Anal Intercourse (CAI)
Tijdsspanne: Baseline and 3 months post-randomization
Self-reported number of condomless anal intercourse episodes with male partners in the prior 3 months, assessed via web-based survey.
Baseline and 3 months post-randomization

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Seul Ki Choi

Medewerkers

Ewha Womans University

Onderzoekers

  • Hoofdonderzoeker: Seul Ki Choi, MPH, PhD, University of Pennsylvania

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 september 2026

Primaire voltooiing (Geschat)

31 maart 2027

Studie voltooiing (Geschat)

30 juni 2027

Studieregistratiedata

Eerst ingediend

28 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

28 juli 2026

Eerst geplaatst (Werkelijk)

3 augustus 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 augustus 2026

Laatste update ingediend die voldeed aan QC-criteria

28 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 26-7236

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

To protect participant privacy under local and international regulations-including South Korea's Personal Information Protection Act (PIPA) and IRB protocols-individual participant data will not be publicly shared. The study involves sensitive sexual health data among a vulnerable population, and local regulatory restrictions prohibit the open release or cross-border sharing of raw individual participant records.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren